Drug intelligence / Profile preview

3804-291

Development stage: Unknown
Lead developer: Dial
Modality: Small Molecules
Administration: Topical

Overview

3804-291 is a topical product developed by The Dial Corporation. It is being evaluated in a Phase II clinical trial for its efficacy in preventing common cold illness, specifically by preventing rhinovirus infection. The product is applied topically, two pumps at a time, at least every four hours or after hand washing.

Beyond the preview

Go deeper on 3804-291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3804-291.

Explore the full profile